These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38467640)

  • 41. Complete dependence on IRAK4 kinase activity in TLR2, but not TLR4, signaling pathways underlies decreased cytokine production and increased susceptibility to Streptococcus pneumoniae infection in IRAK4 kinase-inactive mice.
    Pennini ME; Perkins DJ; Salazar AM; Lipsky M; Vogel SN
    J Immunol; 2013 Jan; 190(1):307-16. PubMed ID: 23209321
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4).
    Wang L; Ferrao R; Li Q; Hatcher JM; Choi HG; Buhrlage SJ; Gray NS; Wu H
    J Biol Chem; 2019 Mar; 294(12):4511-4519. PubMed ID: 30679311
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.
    Smith GF; Altman MD; Andresen B; Baker J; Brubaker JD; Chen H; Chen Y; Childers M; Donofrio A; Ferguson H; Fischer C; Fischmann TO; Gibeau C; Hicks A; Jin S; Kattar S; Kleinschek MA; Leccese E; Lesburg C; Li C; Lim J; Liu D; Maclean JKF; Mansoor F; Moy LY; Mulrooney EF; Necheva AS; Presland J; Rakhilina L; Yang R; Torres L; Zhang-Hoover J; Northrup A
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2721-2726. PubMed ID: 28501511
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity.
    Rajapaksa NS; Gobbi A; Drobnick J; Do S; Kolesnikov A; Liang J; Chen Y; Sujatha-Bhaskar S; Huang Z; Brightbill H; Francis R; Yu C; Choo EF; DeMent K; Ran Y; An L; Emson C; Maher J; Wai J; McKenzie BS; Lupardus PJ; Zarrin AA; Kiefer JR; Bryan MC
    ACS Med Chem Lett; 2020 Mar; 11(3):327-333. PubMed ID: 32184965
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis, and pharmacological evaluation of N-(3-carbamoyl-1H-pyrazol-4-yl)-1,3-oxazole-4-carboxamide derivatives as interleukin-1 receptor-associated kinase 4 inhibitors with reduced potential for cytochrome P450 1A2 induction.
    Inami H; Mizutani T; Watanabe J; Hayashida H; Ito T; Terasawa T; Kontani T; Yamagishi H; Usuda H; Aoyama N; Imamura E; Ishikawa T
    Bioorg Med Chem; 2023 May; 87():117302. PubMed ID: 37201454
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of 5-Aryl-2,4-diaminopyrimidine Compounds as Potent and Selective IRAK4 Inhibitors.
    Chen Y; Singh R; Lin N; Taylor V; Masuda ES; Payan DG
    ACS Med Chem Lett; 2022 Apr; 13(4):714-719. PubMed ID: 35450353
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core.
    Wood MR; Noetzel MJ; Engers JL; Bollinger KA; Melancon BJ; Tarr JC; Han C; West M; Gregro AR; Lamsal A; Chang S; Ajmera S; Smith E; Chase P; Hodder PS; Bubser M; Jones CK; Hopkins CR; Emmitte KA; Niswender CM; Wood MW; Duggan ME; Conn PJ; Bridges TM; Lindsley CW
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3029-3033. PubMed ID: 27185330
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors.
    Bhide RS; Keon A; Weigelt C; Sack JS; Schmidt RJ; Lin S; Xiao HY; Spergel SH; Kempson J; Pitts WJ; Carman J; Poss MA
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4908-4913. PubMed ID: 28947151
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Robust TLR4-induced gene expression patterns are not an accurate indicator of human immunity.
    Brown KL; Falsafi R; Kum W; Hamill P; Gardy JL; Davidson DJ; Turvey S; Finlay BB; Speert DP; Hancock RE
    J Transl Med; 2010 Jan; 8():6. PubMed ID: 20105294
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Innate immune interleukin-1 receptor-associated kinase 4 exacerbates viral myocarditis by reducing CCR5(+) CD11b(+) monocyte migration and impairing interferon production.
    Valaperti A; Nishii M; Liu Y; Naito K; Chan M; Zhang L; Skurk C; Schultheiss HP; Wells GA; Eriksson U; Liu PP
    Circulation; 2013 Oct; 128(14):1542-54. PubMed ID: 24030499
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IRAK4 mediates colitis-induced tumorigenesis and chemoresistance in colorectal cancer.
    Li Q; Chen Y; Zhang D; Grossman J; Li L; Khurana N; Jiang H; Grierson PM; Herndon J; DeNardo DG; Challen GA; Liu J; Ruzinova MB; Fields RC; Lim KH
    JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31527315
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of Potent, Selective, and Brain-Penetrant 1 H-Pyrazol-5-yl-1 H-pyrrolo[2,3- b]pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors.
    Fushimi M; Fujimori I; Wakabayashi T; Hasui T; Kawakita Y; Imamura K; Kato T; Murakami M; Ishii T; Kikko Y; Kasahara M; Nakatani A; Hiura Y; Miyamoto M; Saikatendu K; Zou H; Lane SW; Lawson JD; Imoto H
    J Med Chem; 2019 May; 62(10):4915-4935. PubMed ID: 31009559
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design, synthesis and pharmacological evaluation of 2,3-dihydrobenzofuran IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma.
    Chen Y; Ning Y; Chen Z; Xue Y; Wu Q; Duan W; Ding J; Zhou J; Xie H; Zhang H
    Eur J Med Chem; 2023 Aug; 256():115453. PubMed ID: 37163947
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IRAK4 kinase activity is required for Th17 differentiation and Th17-mediated disease.
    Staschke KA; Dong S; Saha J; Zhao J; Brooks NA; Hepburn DL; Xia J; Gulen MF; Kang Z; Altuntas CZ; Tuohy VK; Gilmour R; Li X; Na S
    J Immunol; 2009 Jul; 183(1):568-77. PubMed ID: 19542468
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recent Progress in the Molecular Recognition and Therapeutic Importance of Interleukin-1 Receptor-Associated Kinase 4.
    Patra MC; Choi S
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27845762
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deficiency in IRAK4 activity attenuates manifestations of murine Lupus.
    Murphy M; Pattabiraman G; Manavalan TT; Medvedev AE
    Eur J Immunol; 2017 May; 47(5):880-891. PubMed ID: 28295231
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018).
    McElroy WT
    Expert Opin Ther Pat; 2019 Apr; 29(4):243-259. PubMed ID: 30916602
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML.
    Bennett J; Ishikawa C; Agarwal P; Yeung J; Sampson A; Uible E; Vick E; Bolanos LC; Hueneman K; Wunderlich M; Kolt A; Choi K; Volk A; Greis KD; Rosenbaum J; Hoyt SB; Thomas CJ; Starczynowski DT
    Blood; 2023 Sep; 142(11):989-1007. PubMed ID: 37172199
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Involvement of Interleukin-1 Receptor-Associated Kinase 4 and Interferon Regulatory Factor 5 in the Immunopathogenesis of SARS-CoV-2 Infection: Implications for the Treatment of COVID-19.
    Stoy N
    Front Immunol; 2021; 12():638446. PubMed ID: 33936053
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of the interleukin 1 receptor-associated kinase 4 (IRAK4)-encoding gene in salmonid fish: the functional copy is rearranged in Oncorhynchus mykiss and that factor can impair TLR signaling in mammalian cells.
    Brietzke A; Goldammer T; Rebl H; Korytář T; Köllner B; Yang W; Rebl A; Seyfert HM
    Fish Shellfish Immunol; 2014 Jan; 36(1):206-14. PubMed ID: 24239597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.